Abstract: The present invention provides a method and a kit for detecting a S. pneumoniae nucleic acid in a sample. The method comprises the steps of isolating said nucleic acid and detecting hybridization between the S. pneumoniae nucleic acid and a labeled probe, wherein the detection of hybridization comprises detecting a change in signal from the labeled probe during or after hybridization relative to the labeled probe signal before hybridization. The method of the present invention is characterized in that said nucleic acid is a ribonucleic acid, which isolation comprises the addition of acidic phenol to said sample and the purification of said ribonucleic acid.

Abstract: Disclosed is a method of diagnosing the presence of higher grade astrocytoma/glioblastoma (GBM) or lower-grade astrocytoma (DA or AA) in a human subject using secreted or plasma membrane associated biomarkers, which involves the detection of the expression levels of said genes, alone or in combination, in either tumor tissue samples or body fluids and a diagnostic kit thereof.

Abstract: The present invention relates to a method for differentiating in a subject with HR-HPV between a severe form of HR-HPV infection and a mild form of HR-HPV infection. It further is concerned with a composition comprising a probe oligonucleotide mixture, a device, and a kit for use in conjunction with the method of the invention.

Abstract: Clinical tests for testing therapeutic sensitivity of cancerous breast tissue and methods and kits for performing the same are described herein. Embodiments of the present invention are directed to methods for predicting the efficacy of treatment of breast cancer. In addition, certain embodiments are directed to a kit for testing therapeutic sensitivity of breast cancer tissue.

Abstract: Methods of capturing two or more nucleic acids simultaneously from a single sample are provided. Different nucleic acids are captured through cooperative hybridization events on different subsets of particles or at different selected positions on a spatially addressable solid support. Methods of capturing one or more long nucleic acids and methods of capturing one or more nucleic acid for sequencing are also provided. Compositions, kits, and systems related to the methods are also described.

Abstract: An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1.

Abstract: The present invention is based in part on the discovery of a panel of miRs whose levels are increased or decreased in the circulation of chronic systolic HF patients. Accordingly, an extensive panel of miRs was screened in the sera of stable chronic systolic HF patients and the results were compared to an age, gender and ethnically matched control group.

Abstract: The present invention is directed to the discovery of single nucleotide polymorphisms (SNPs) in the presence of metronidazole-resistant Trichomonas vaginalis. The presence of G76C, C213G, or C318A (SNP) in tvntr 4 or the presence of A238T, G427C, or T476C (SNP) in tvntr6 provides a reliable biomarker for the presence of metronidazole-resistant Trichomonas vaginalis. The present invention further provides reagents used for detecting the SNPs to screen subjects for metronidazole resistance in Trichomonas vaginalis.

Abstract: The present invention provides a method of diagnosing a cerebrovascular disease in a human comprising the steps of: (a) measuring a mutation of HTRA1 gene in a test sample from said human; and (b) determining if the mutation of HTRA1 gene in said test sample correlates with a cerebrovascular disease in said human.

Abstract: This application provides materials and methods for the detection of the aad-12 gene and event pDAB4472-1606 in biological samples derived from plants.

Abstract: Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (DDR2) gene.

Abstract: A method for predicting a subject's risk factors for CYP3A4-related disorders includes detecting the allelic status of a SNP in a nucleic acid sample of the subject.

Abstract: This invention relates generally to the THAP1 gene and mutations in this gene, as well as the THAP1 protein and mutations in this protein, that are associated with dystonia. The invention relates to the identification, isolation, cloning and characterization of the DNA sequence corresponding to the wild type and mutant THAP1 genes, as well as isolation and characterization of their transcripts and gene products. The invention further relates to methods and kits useful for detecting mutations in THAP1 that are associated with dystonia, as well as to methods and kits useful for diagnosing dystonia. The present invention also relates to therapies for treating dystonia, including gene therapeutics and protein/antibody based therapeutics.

Abstract: The present invention relates to a non-amphiphile-based water-in-water emulsion composition. The non-amphiphile-based water-in-water emulsion composition includes a water-soluble polymer, a non-amphiphilic lyotropic mesogen encapsulated by the water-soluble polymer; and water. In one embodiment, the non-amphiphilic lyotropic mesogen includes, without limitation, a lyotropic chromonic liquid crystal, and more specifically disodium cromoglycate (DSCG). In another embodiment, the water-soluble polymer can include, without limitation, a polyacrylamide, a polyol, a polyvinylpyrrolidone, a polysaccharide, or a water-soluble fluoride-bearing polymer. The present invention also relates to a porous hydrogel made with the use of the non-amphiphile-based water-in-water emulsion. The present invention further relates to using the emulsion and hydrogel for various applications.

Abstract: The present disclosure describes the identification of single nucleotide polymorphisms (SNPs) in inflammatory diseases and uses thereof, and methods of screening for, diagnosing, identifying susceptibility to or detecting a risk of developing an inflammatory disease comprising detecting the presence or absence of at least one SNP identified in a gene associated with inflammatory disease.

Abstract: Disclosed are primer set compositions, methods and kits for human identification using the highly complex sequence locus, SE33 (ACTBP2) in single and multiplex PCR reactions. Additionally, disclosed are three newly discovered single nucleotide polymorphisms (SNPs) within the SE33 locus that can cause discordance seen as mobility shift or allelic dropout. Also disclosed are kits useful in human identification.

Abstract: Single nucleotide polymorphic sites at positions 19069 and 25402 of the bovine STAT3 gene are associated with improved fertilization rate and/or improved embryo survival rate. The interactions between these two polymorphisms, and between them and the bovine STAT1 gene and fertilization and early embryonic survival rates were also disclosed. The interactions between STAT3 SNPs, and between STAT1 and STAT3 SNP19069 were highly significant for embryonic survival rate. Also disclosed are nucleic acid molecules, kits, methods of genotyping and marker assisted bovine breeding methods.

Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.

Abstract: The present invention relates to the identification of loss-of-function mutations in the filaggrin gene and their use in diagnosing ichthyosis vulgaris and/or susceptibility to other diseases including atopic dermatitis (eczema), asthma, psoriasis and allergies (including food allergy).

Abstract: The present invention discloses certain genetic variants as susceptibility variants for peripheral arterial disease (PAD) and abdominal aortic aneurysm (AAA). The invention relates to risk management using such variants. The invention further relates to kits for use in risk assessment of PAD and AAA.